These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 3047432)

  • 1. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.
    Murphy BR; Olmsted RA; Collins PL; Chanock RM; Prince GA
    J Virol; 1988 Oct; 62(10):3907-10. PubMed ID: 3047432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
    Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
    Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV).
    Murphy BR; Prince GA; Collins PL; Hildreth SW; Paradiso PR
    Vaccine; 1991 Mar; 9(3):185-9. PubMed ID: 2042390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.
    Murphy BR; Prince GA; Walsh EE; Kim HW; Parrott RH; Hemming VG; Rodriguez WJ; Chanock RM
    J Clin Microbiol; 1986 Aug; 24(2):197-202. PubMed ID: 3755730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppression of the antibody response to respiratory syncytial virus (RSV) by pre-existing serum antibodies: partial prevention by topical infection of the respiratory tract with vaccinia virus-RSV recombinants.
    Murphy BR; Collins PL; Lawrence L; Zubak J; Chanock RM; Prince GA
    J Gen Virol; 1989 Aug; 70 ( Pt 8)():2185-90. PubMed ID: 2671259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity.
    Johnson PR; Olmsted RA; Prince GA; Murphy BR; Alling DW; Walsh EE; Collins PL
    J Virol; 1987 Oct; 61(10):3163-6. PubMed ID: 3305988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection.
    Murphy BR; Alling DW; Snyder MH; Walsh EE; Prince GA; Chanock RM; Hemming VG; Rodriguez WJ; Kim HW; Graham BS
    J Clin Microbiol; 1986 Nov; 24(5):894-8. PubMed ID: 3771779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus.
    Olmsted RA; Buller RM; Collins PL; London WT; Beeler JA; Prince GA; Chanock RM; Murphy BR
    Vaccine; 1988 Dec; 6(6):519-24. PubMed ID: 3072795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein.
    Elango N; Prince GA; Murphy BR; Venkatesan S; Chanock RM; Moss B
    Proc Natl Acad Sci U S A; 1986 Mar; 83(6):1906-10. PubMed ID: 3513191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.
    Connors M; Kulkarni AB; Collins PL; Firestone CY; Holmes KL; Morse HC; Murphy BR
    J Virol; 1992 Feb; 66(2):1277-81. PubMed ID: 1731105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats.
    Prince GA; Horswood RL; Chanock RM
    J Virol; 1985 Sep; 55(3):517-20. PubMed ID: 4020957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.
    Olmsted RA; Elango N; Prince GA; Murphy BR; Johnson PR; Moss B; Chanock RM; Collins PL
    Proc Natl Acad Sci U S A; 1986 Oct; 83(19):7462-6. PubMed ID: 3532115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.
    Murphy BR; Walsh EE
    J Clin Microbiol; 1988 Aug; 26(8):1595-7. PubMed ID: 2459154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3.
    Homa FL; Brideau RJ; Lehman DJ; Thomsen DR; Olmsted RA; Wathen MW
    J Gen Virol; 1993 Sep; 74 ( Pt 9)():1995-9. PubMed ID: 8397289
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection.
    Walsh EE; Hall CB; Briselli M; Brandriss MW; Schlesinger JJ
    J Infect Dis; 1987 Jun; 155(6):1198-204. PubMed ID: 3553346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee.
    Hsu KH; Lubeck MD; Davis AR; Bhat RA; Selling BH; Bhat BM; Mizutani S; Murphy BR; Collins PL; Chanock RM
    J Infect Dis; 1992 Oct; 166(4):769-75. PubMed ID: 1527411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection.
    Murphy BR; Graham BS; Prince GA; Walsh EE; Chanock RM; Karzon DT; Wright PF
    J Clin Microbiol; 1986 Jun; 23(6):1009-14. PubMed ID: 3754878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.